Emergent BioSolutions Inc.

NYQ: EBS

Live Quote

📈 ZcoreAI Score

Our AI model analyzes Emergent BioSolutions Inc.'s price action across multiple timeframes using regression channels and statistical scoring.

Get EBS Z-Score →

About Emergent BioSolutions Inc.

Healthcare Drug Manufacturers - Specialty & Generic

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

📊 Fundamental Analysis

Emergent BioSolutions Inc. demonstrates a profit margin of 7.1%, which is below the sector average, suggesting competitive pressure.

The company recently reported -23.6% revenue growth, which is negative, indicating a recent decline in revenue.

Return on Equity (ROE) is 10.5%, which suggests room for improvement in capital utilization.

At a current price of $7.96, EBS currently sits at the 37th percentile of its 52-week range (Range: $4.34 - $14.06).

💰 Valuation Insight

EBS trades at a 65.8% discount (PE: 8.56), which may represent a value opportunity given the sector average of 25.00. Analysts expect earnings growth, as indicated by a lower forward PE.

🏥 Financial Health

🔴 Profit Margin Weak

🔴 Debt/Equity Elevated

🔴 Revenue Growth Weak

🔴 Return on Equity Weak

🔴 Beta (Risk) High Volatility

Key Financials

Market Cap

$412.10M

Trailing P/E

8.56

Forward P/E

2.66

Beta (5Y)

2.36

52W High

$14.06

52W Low

$4.34

Avg Volume

944K

Day High

Day Low

Get EBS Z-Score on Dashboard 🚀